Definitive Contract HHSN272201500023C
Award Date
7/24/15
Potential Completion Date
7/31/16
Potential Value
$225K
Federal Agency
NIAID DEA OA Acquisitions
Awardee
Aerophase, Inc.
Ultimate Awardee
Not listed
NAICS Category
541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
PSC Category
AN81 - R&D- Medical: Aids Research (Basic Research)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Loveland, CO, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
5
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Northbound Therapeutics, Inc., a minority-owned, woman-owned small business, to develop an inhaled clofazimine powder as a novel treatment for multidrug-resistant tuberculosis (MDR-TB). The contract, valued at $37,500, is for the formulation and preclinical evaluation of the inhaled clofazimine powder. This SBIR contract is a Firm Fixed Price...
This federal contract award was made by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Creare LLC, doing business as Creare, a small business engineering research and development company. The $591,870.00 Small Business Innovation Research (SBIR) Phase I contract is for the development of an optimized dry powder formulation and delivery system for the anti-tuberculosis drug clofazimine. The...
This contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Qrumpharma, Inc., a self-certified small disadvantaged business, for a Small Business Innovation Research (SBIR) Program Phase I project. The objective is to determine the feasibility of a clofazimine inhalation formulation for preclinical development in tuberculosis. The contract is a definitive contract with a firm...
This is a $1,486,937 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to PAI Life Sciences Inc., a self-certified small disadvantaged business. The contract is for the development of an inhaled drug combination for tuberculosis therapy under the SBIR Phase II program. Key tasks include the manufacture of spray-dried combination drugs, technical support for pharmacokinetic and...
This federal contract award, valued at $210,507.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID) to PAI Life Sciences Inc., a self-certified small disadvantaged business, for the "AEROSOLIZED DELIVERY OF ANTI-TUBERCULAR DRUGS" project. The contract is a Definitive Contract with a Firm Fixed Price pricing type. PAI Life Sciences will be the prime contractor, and Research Triangle Institute (RTI International), a non-profit research organization, will...
Via Therapeutics, LLC has been awarded a firm fixed price definitive contract valued at $3,599,145 by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases. This contract is set aside for small businesses and will support Phase I of Via Therapeutics' SBIR program efforts to develop an inhaled delivery method for clofazimine, an important drug for treating tuberculosis. The contract aligns with the agency's solicitation...
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $299,995 firm fixed-price contract to Via Therapeutics, LLC, a small business located in Austin, Texas. The contract is for the development of low-cost, shelf-stable, patient-adaptable clofazimine mini-tablets to treat tuberculosis in pediatric patients. This contract supports Via Therapeutics' pharmaceutical research and development efforts related to...
This is a SBIR Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the Department of Health and Human Services (HHS), to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The contract has a firm fixed price of $300,000.00 and is for the development of a point-of-care test to measure antibiotic concentrations in the blood for tuberculosis (TB) treatment. Nanocomposix has prior experience providing products...
This is a $224,284 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Aucta Pharmaceuticals LLC, a Minority Owned Business, For Profit Organization, Asian-Pacific American Owned, Limited Liability Company. The contract is for a "MULTIPARTICULATE DISPERSIVE TABLET FOR PEDIATRIC ANTI-TB" under the SBIR Program Phase I Action. It is a Definitive Contract and is set aside for a Total Small Business. The contract has an ultimate...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, awarded a $220,582 Small Business Innovation Research (SBIR) Phase I contract to Oak Therapeutics Inc., a pharmaceutical company based in Westlake Village, California. The contract is for the development of oral dissolving strips for the delivery of isoniazid, a medication used to treat tuberculosis, in children and adults. This contract is a Firm Fixed Price definitive...